Influenza Virus Vaccine, Inactivated Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Influenza Prophylaxis

0.5 mL once by intramuscular injection

or

Fluzone Intradermal - 18 through 64 years: 0.1 mL once by intradermal injection

Usual Geriatric Dose for Influenza Prophylaxis

65 years or older:
influenza virus vaccine, inactivated high-dose preservative-free intramuscular suspension (Fluzone High Dose):
0.5 mL once by intramuscular injection

Usual Pediatric Dose for Influenza Prophylaxis

Afluria:
Children 5 years through 8 years of age not previously vaccinated with an influenza vaccine, or vaccinated for the first time last season with only one dose: Administer two 0.5 mL doses by intramuscular injection, one on Day 1 and another approximately 4 weeks later.
Children 5 years through 8 years of age given two doses last season, or at least one dose two or more years ago: Administer a single 0.5 mL dose by intramuscular injection.
Children 9 years of age and older: Administer a single 0.5 mL dose by intramuscular injection.

Note: Although approved for use in children 5 years to 8 years of age, the ACIP does not recommend use of Afluria in infants or children less than 8 years of age due to an increased incidence of fever and febrile seizures noted during the 2010 to 2011 influenza season. However, if other age appropriate vaccines are not available, children 5 to 8 years of age who are also considered at risk for influenza complications may be given Afluria after benefits and risks are discussed with parents or caregivers.

Fluzone:
6 months to 35 months: 0.25 mL by intramuscular injection (1 or 2 doses).
3 years to 8 years: 0.5 mL by intramuscular injection (1 or 2 doses).
Previously unvaccinated children 6 months to less than 9 years of age should receive 2 doses, given more than 1 month apart in order to achieve a satisfactory antibody response. Second dose should preferably be administered before the onset of influenza season.
9 years or older: 0.5 mL once by intramuscular injection.

Fluvirin:
4 to 8 years of age: 0.5 mL dose via intramuscular injection, one or two doses.
Children aged 4 to 8 years should receive 2 doses of vaccine separated by at least 4 weeks, if they have not been vaccinated previously at any time with any influenza virus vaccine. Children aged 4 to 8 years who received only 1 dose in their first year of vaccination in the previous season should receive 2 doses of vaccine separated by at least 4 weeks. Children aged 4 to 8 years who have been vaccinated with two doses of any influenza virus vaccine in the previous season, or with one dose in the year prior to the previous season, should receive only one dose.
9 years and older: A single 0.5 mL intramuscular injection.

Fluarix or Flulaval:
3 years to 8 years of age previously unvaccinated or vaccinated for the first time last season with only one dose receive two 0.5 mL doses; each 0.5 mL dose is administered at least 4 weeks apart. Children 3 years to 8 years of age previously vaccinated with 2 doses of any influenza vaccine receive only one 0.5 mL dose.
Children 9 years of age and older receive only one 0.5 mL dose.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Influenza virus vaccine, inactivated is considered contraindicated in individuals with known systemic hypersensitivity reaction to egg proteins (eggs or egg products), chicken proteins, or who have experienced a life-threatening reaction related to previous administration of influenza vaccine or a vaccine containing the same substances.

It is recommended to postpone administration of the vaccine in individuals with febrile or acute disease. In addition, it is recommended to delay administration to individuals with an active neurologic disorder until the disease process has stabilized.

Administration should be avoided in individuals who have a prior history of Guillain-Barre syndrome (GBS).

The FDA has updated the Prescribing Information for Afluria by CSL to inform healthcare professionals that the vaccine has been associated with an increased incidence of fever and febrile seizure among young children reported in Australia, mainly among those less than 5 years of age. The available data suggest that the increased rates of fever and febrile seizure are only associated with the 2010 Southern Hemisphere formulation of CSL's vaccine.

Dialysis

Data not available

Other Comments

Administration Advice:
Shake well before administration.
It is recommended to administer in the region of the deltoid muscle in adults and older children and in the region of the anterolateral aspect of the thigh in infants and young children. The vaccine should not be administered in the gluteal area or areas where there may be a major nerve trunk.

Do not inject intravenously.

It is important to note that influenza seasons vary in their timing and duration from year to year. In general, vaccination should begin soon after the vaccine becomes available and if possible, prior to October. However, vaccination should continue throughout the influenza season as long as vaccine is available.

Hide
(web2)